Clinical Trial Update: Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas [Phase 1]

View source ↗

Summary

A Phase I study at Johns Hopkins evaluated orally administered aminolevulinic acid for fluorescence-guided resection of malignant astrocytomas; the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioma

Drugs mentioned

• Aminolevulinic acid (5-aminolevulinic acid)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Astrocytoma, Glioma | Phase 1 | Status: TERMINATED